Neoadjuvant chemotherapy improves survival in resectable pancreatic cancer.

Neoadjuvant chemotherapy using gemcitabine and S-1 significantly outperforms upfront surgery for patients with resectable pancreatic ductal adenocarcinoma (PDAC). In a randomized trial with 364 participants, median overall survival was 37.0 months for the chemotherapy group compared to 26.6 months for the surgery group, with a hazard ratio of 0.73. Additionally, median relapse-free survival was extended from 11.3 to 14.3 months. These findings underline the potential of neoadjuvant treatment in improving patient outcomes.